Novel therapies in genitourinary cancer: an update

In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical oncologists and urologists are progressively more hopeful for better outcomes. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, David, Wu, Shenhong
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527326/
https://www.ncbi.nlm.nih.gov/pubmed/18694493
http://dx.doi.org/10.1186/1756-8722-1-11
_version_ 1782158800679075840
author Chu, David
Wu, Shenhong
author_facet Chu, David
Wu, Shenhong
author_sort Chu, David
collection PubMed
description In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical oncologists and urologists are progressively more hopeful for better outcomes. The new remedies may provide patients with improved survival and at the same time less toxicity when compared to traditional cytotoxic agents. This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting.
format Text
id pubmed-2527326
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-25273262008-08-30 Novel therapies in genitourinary cancer: an update Chu, David Wu, Shenhong J Hematol Oncol Review In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical oncologists and urologists are progressively more hopeful for better outcomes. The new remedies may provide patients with improved survival and at the same time less toxicity when compared to traditional cytotoxic agents. This article will center on current and emerging treatment strategies for advanced RCC and other GU malignancies with updates from 2008 annual ASCO meeting. BioMed Central 2008-08-11 /pmc/articles/PMC2527326/ /pubmed/18694493 http://dx.doi.org/10.1186/1756-8722-1-11 Text en Copyright © 2008 Chu and Wu; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Chu, David
Wu, Shenhong
Novel therapies in genitourinary cancer: an update
title Novel therapies in genitourinary cancer: an update
title_full Novel therapies in genitourinary cancer: an update
title_fullStr Novel therapies in genitourinary cancer: an update
title_full_unstemmed Novel therapies in genitourinary cancer: an update
title_short Novel therapies in genitourinary cancer: an update
title_sort novel therapies in genitourinary cancer: an update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2527326/
https://www.ncbi.nlm.nih.gov/pubmed/18694493
http://dx.doi.org/10.1186/1756-8722-1-11
work_keys_str_mv AT chudavid noveltherapiesingenitourinarycanceranupdate
AT wushenhong noveltherapiesingenitourinarycanceranupdate

Ejemplares similares